Professor Shi Yuankai Confirmed to Attend the 2019 Future Healthcare 100 Summit

December 20–22, 2019 (Friday–Sunday), the annual Future Healthcare Top 100 Conference will be held atBeijing · Jiuhua VillaHeld as an annual flagship event for discussions on trends in the healthcare industry, the forum features“New Growth in Life”Focusing on the triple factors of policy environment, technological landscape, and demand space, this analysis comprehensively interprets future development trends in the healthcare industry to drive innovative transformation in health and medical sectors.

Professor Shi Yuankai, Deputy Director of the National Cancer Center and Vice President of the Cancer Hospital, Chinese Academy of Medical SciencesConfirm attendance at “New Growth in Life” – The 2019 Future Healthcare Top 100 Conference.

Professor Shi Yuankai, Chief Physician and Doctoral Supervisor, serves as Deputy Director of the National Cancer Center, Vice President of the Cancer Hospital of the Chinese Academy of Medical Sciences, Deputy Director of the National Clinical Research Center for New Drugs (Antineoplastic Agents), Director of the Beijing Key Laboratory of Clinical Research on Antitumor Molecular Targeted Drugs, Head of the Academic Department of the China Anti-Cancer Association, Former Chairman of the Professional Committee on Clinical Chemotherapy of the China Anti-Cancer Association, President of the Oncology Branch of the Chinese Medical Doctor Association, and Chairman of the Professional Committee on Antineoplastic Drugs of the Chinese Pharmaceutical Association.

Presided over more than 30 national and local-level research projects, conducted over 170 clinical studies on anti-tumor drugs and related fields, including more than 60 studies on Class I new drugs developed by Chinese enterprises. Published over 250 articles as the first or corresponding author, served as editor-in-chief or chief translator for more than 20 books, led the development of over 10 national diagnostic and treatment guidelines and expert consensus statements, and received one First Prize of the National Science and Technology Progress Award, multiple provincial and ministerial-level Science and Technology Progress Awards, and several national invention patents.

Professor Shi Yuankai is a renowned expert in medical oncology in China. Over the years, he has undertaken multiple national key research projects under the “Ninth Five-Year Plan” and several grants from the National Natural Science Foundation of China, making outstanding contributions particularly in the field of hematopoietic stem cell transplantation for cancer.

Since the 21st century, cancer treatment has entered the era of targeted and immunotherapy. Professor Shi Yuankai participated in the research and development of icotinib and chidamide, small-molecule targeted anticancer drugs with independent intellectual property rights, and established China’s first clinical evaluation research technology platform for new anti-tumor drugs, thereby promoting the research and development of related innovative drugs.

On December 21, Professor Shi Yuankai, Deputy Director of the National Cancer Center and Vice President of the Cancer Hospital of the Chinese Academy of Medical Sciences, will attend the Innovative Drug Forum of the 2019 Future Healthcare 100 Conference, hosted by VCBeat and Eggshell Research Institute, to share insights on the current status and prospects of novel anti-tumor drug development in China.

“Top 100 Future Healthcare Conference” is an annual flagship event hosted by VCBeat, aiming to unite core industry forces and drive the transformation of the innovative healthcare sector. Leveraging the release of the “Top 100 Future Healthcare” list and its associated awards, the conference brings together the most dynamic healthcare innovation enterprises, listed companies, financial institutions, and medical organizations from both China and abroad, fostering effective interaction and collaboration across the industry chain.

December 20-22, the 2019 Future Healthcare 100 Conference, hosted by VCBeat and Eggshell Research Institute, will grandly open at Jiuhua Resort in Beijing.

Five Major Product Pillars: Five Themed Summits and Over Ten Sub-Forum Tracks, the Future Healthcare 100 Rankings and Awards Series, the Future Healthcare 100 Report Series, the Future Healthcare 100 Exhibition, and a Series of Networking Events.

Among them, the forums include:Future Healthcare Main Forum, Top 100 Summit, Future Healthcare Leaders Summit, Future Healthcare Cross-Industry Summit, Health & Medical Fund Partners Summit, China-Japan Health Industry Development Forum, Healthy City Development Forum, Innovative Drug Forum, Innovative Health Insurance Forum, Digital Pathology & Precision Diagnostics Forum, Health Management Forum, Consumer Healthcare Forum, Internet Hospital Forum, Smart Hospital Construction Forum, Pharmaceutical Digital Marketing Forum, Biotechnology Forum, Medical AI Forum。

Also"Report on the Future Industry Tree," "Analysis Report of the 2019 Top 100 Future Healthcare Companies," "2019 Development Report on the Medical Artificial Intelligence Industry," "2019 Development Report on the Internet Hospital Industry," "Report on Digital Innovation in Pharmaceuticals"Over 10 thematic reports were released on-site.

Whether you are from a publicly listed healthcare company, an innovative enterprise, an investment firm, an industry fund, a securities institution, a medical institution, or if you are a researcher, university student, government guest, or healthcare industry media representative, this industry forum is tailor-made for “you.”

You’re Just One Ticket Away from Industry Titans